Skip to main content
Top
Published in: PharmacoEconomics 6/2018

01-06-2018 | Commentary

Once Bitten Twice Shy: Thinking Carefully Before Adopting the EQ-5D-5L

Author: Jeff Round

Published in: PharmacoEconomics | Issue 6/2018

Login to get access

Excerpt

The Euro-Qol group introduced the EQ-5D-5L descriptive system in 2009 [1], with the first publication describing the tool appearing in 2011 [2]. This revised version of the EQ-5D instrument introduced five response levels, alongside changes to the wording used to describe responses in the mobility domain. The five-level version of the EQ-5D descriptive system was developed in response to perceived failings of the three response-level EQ-5D-3L, notably in its sensitivity to changes in health [3], but also ceiling effects [2] and an ‘uneven’ distribution of responses as measured by the valuation tariff [4]. …
Literature
2.
4.
go back to reference Devlin NJ, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.CrossRefPubMed Devlin NJ, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22.CrossRefPubMed
5.
go back to reference Brazier J, Briggs A, Bryan S. EQ-5D-5L: Smaller steps but a major step change? Health Econ. 2018;27(1):4–6.CrossRefPubMed Brazier J, Briggs A, Bryan S. EQ-5D-5L: Smaller steps but a major step change? Health Econ. 2018;27(1):4–6.CrossRefPubMed
6.
go back to reference Hernandez Alava M, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.CrossRefPubMed Hernandez Alava M, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.CrossRefPubMed
7.
go back to reference National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L valuation set. London: NICE; 2017. National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L valuation set. London: NICE; 2017.
9.
go back to reference Konerding U, et al. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014;12:181.CrossRefPubMedPubMedCentral Konerding U, et al. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries. Health Qual Life Outcomes. 2014;12:181.CrossRefPubMedPubMedCentral
10.
go back to reference Jensen-Dahm C, et al. Discrepancy between self- and proxy-rated pain in Alzheimer’s disease: results from the Danish Alzheimer Intervention Study. J Am Geriatr Soc. 2012;60(7):1274–8.CrossRefPubMed Jensen-Dahm C, et al. Discrepancy between self- and proxy-rated pain in Alzheimer’s disease: results from the Danish Alzheimer Intervention Study. J Am Geriatr Soc. 2012;60(7):1274–8.CrossRefPubMed
11.
go back to reference Ramakers GG, et al. Agreement between health utility instruments in cochlear implantation. Clin Otolaryngol. 2016;41(6):737–43.CrossRefPubMed Ramakers GG, et al. Agreement between health utility instruments in cochlear implantation. Clin Otolaryngol. 2016;41(6):737–43.CrossRefPubMed
12.
go back to reference Dickerson JF, et al. Evidence on the longitudinal construct validity of major generic and utility measures of health-related quality of life in teens with depression. Qual Life Res. 2017. Dickerson JF, et al. Evidence on the longitudinal construct validity of major generic and utility measures of health-related quality of life in teens with depression. Qual Life Res. 2017.
13.
go back to reference Janssen MF, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.CrossRefPubMed Janssen MF, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–27.CrossRefPubMed
14.
go back to reference Brazier J, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34):vii–viii, xiii–xxv, 1–188.CrossRef Brazier J, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34):vii–viii, xiii–xxv, 1–188.CrossRef
15.
go back to reference Mulhern B, et al. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry. 2014;205(3):236–43.CrossRefPubMed Mulhern B, et al. Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry. 2014;205(3):236–43.CrossRefPubMed
16.
go back to reference Noyes J, Edwards RT. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. Value Health. 2011;14(8):1117–29.CrossRefPubMed Noyes J, Edwards RT. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. Value Health. 2011;14(8):1117–29.CrossRefPubMed
17.
go back to reference Bailey C, et al. ‘The ICECAP-SCM tells you more about what I’m going through’: A think-aloud study measuring quality of life among patients receiving supportive and palliative care. Palliat Med. 2016;30(7):642–52.CrossRefPubMedPubMedCentral Bailey C, et al. ‘The ICECAP-SCM tells you more about what I’m going through’: A think-aloud study measuring quality of life among patients receiving supportive and palliative care. Palliat Med. 2016;30(7):642–52.CrossRefPubMedPubMedCentral
18.
go back to reference Brazier JE, et al. First validation of the short recovering quality of life (ReQoL) measure. Qual Life Res. 2016;25:96. Brazier JE, et al. First validation of the short recovering quality of life (ReQoL) measure. Qual Life Res. 2016;25:96.
19.
go back to reference Stevens K. Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation. Appl Health Econ Health Policy. 2011;9(3):157–69.CrossRefPubMed Stevens K. Assessing the performance of a new generic measure of health-related quality of life for children and refining it for use in health state valuation. Appl Health Econ Health Policy. 2011;9(3):157–69.CrossRefPubMed
20.
go back to reference Huynh E, et al. Values for the ICECAP-Supportive Care Measure (ICECAP-SCM) for use in economic evaluation at end of life. Soc Sci Med. 2017;189:114–28.CrossRefPubMed Huynh E, et al. Values for the ICECAP-Supportive Care Measure (ICECAP-SCM) for use in economic evaluation at end of life. Soc Sci Med. 2017;189:114–28.CrossRefPubMed
22.
go back to reference National Institute for Clinical Excellence, Guide to the Methods of Technology Appraisal. 2004. National Institute for Clinical Excellence. National Institute for Clinical Excellence, Guide to the Methods of Technology Appraisal. 2004. National Institute for Clinical Excellence.
23.
go back to reference National Institute for Health and Clinical Excellence, Guide to the methods of technology appraisal. 2008. National Institute for Health and Clinical Excellence, Guide to the methods of technology appraisal. 2008.
24.
go back to reference Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–76.CrossRefPubMed Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–76.CrossRefPubMed
25.
go back to reference Dolan P, Layard R, Metcalfe R. Measuring Subjective Wellbeing for Public Policy: Recommendations on Measures. 2011. Dolan P, Layard R, Metcalfe R. Measuring Subjective Wellbeing for Public Policy: Recommendations on Measures. 2011.
26.
27.
go back to reference McCrone P, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12(1):27–31.PubMed McCrone P, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12(1):27–31.PubMed
28.
go back to reference Sayah FA, et al. Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. Qual Life Res. 2017;26(8):2057–66.CrossRefPubMed Sayah FA, et al. Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. Qual Life Res. 2017;26(8):2057–66.CrossRefPubMed
29.
30.
go back to reference Dritsaki M, et al. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand. Health Qual Life Outcomes. 2017;15(1):20.CrossRefPubMedPubMedCentral Dritsaki M, et al. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand. Health Qual Life Outcomes. 2017;15(1):20.CrossRefPubMedPubMedCentral
Metadata
Title
Once Bitten Twice Shy: Thinking Carefully Before Adopting the EQ-5D-5L
Author
Jeff Round
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 6/2018
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-018-0636-3

Other articles of this Issue 6/2018

PharmacoEconomics 6/2018 Go to the issue